Status and phase
Conditions
Treatments
About
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Full description
This study consists of Phase 1a dose escalation, Phase 1b dose expansion in a single indication, and Phase 2a expansion in a single indication.
Primary Objectives
Secondary Objectives:
The expected duration of study intervention for patients may vary, based on progression date. The median expected duration of study per patient is estimated to be 10 months (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for long term follow-up).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
115 participants in 4 patient groups
Loading...
Central trial contact
Email recommended
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal